Compare Amphastar Pharmaceuticals Inc (AMPH) vs Fortinet Inc (FTNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Fortinet Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Fortinet Inc trades at $158.15 (market cap $115.40B). The key difference: Fortinet Inc is far larger — about 139.7× Amphastar Pharmaceuticals Inc's market cap, and Fortinet Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | FTNT | |
|---|---|---|
Market Cap | $826.08M | $115.40B |
Sector | Health | Technology |
52-Week High | $30.81 | $163.73 |
52-Week Low | $16.87 | $74.39 |
Enterprise Value | $1.22B | $112.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Fortinet (FTNT) trades at $157.51, down 3.8% over the past day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.82 versus $0.619 expected, and maintains robust profitability with a net income margin of 27.49%. Recent news highlights AI-driven cybersecurity demand as a growth catalyst, with the stock up significantly year-to-date.
The outlook remains positive due to sustained earnings beats and sector tailwinds, but high valuation multiples (P/E of 61.05) and competitive pressures pose risks. Analyst consensus is mixed with 42.65% buy ratings, yet the consensus price target of $117.42 suggests caution relative to the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →
